Agnete Brunsvik Fredriksen
Founder chez NYKODE THERAPEUTICS
Fortune : 4 M $ au 31/03/2024
Profil
Agnete Brunsvik Fredriksen is the founder of Nykode Therapeutics ASA, a company founded in 2007, where she holds the title of Chief Business Officer starting in 2021.
She is currently working as an Independent Director at Molecular Partners AG since 2021 and as a Director at Viginti AS.
Dr. Fredriksen has previously worked as a Director-Life Science at the University of Oslo, as a Researcher at Medinnova AS, and as a Researcher at Affitech A.
She has a graduate degree from the University of Oslo and obtained her doctorate in 2007 from the same institution.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NYKODE THERAPEUTICS ASA
0,91% | 18/12/2022 | 2 982 900 ( 0,91% ) | 4 M $ | 31/03/2024 |
Postes actifs de Agnete Brunsvik Fredriksen
| Sociétés | Poste | Début |
|---|---|---|
| NYKODE THERAPEUTICS | Founder | 01/01/2007 |
| MOLECULAR PARTNERS AG | Director/Board Member | 21/04/2021 |
| Viginti AS | Director/Board Member | - |
Anciens postes connus de Agnete Brunsvik Fredriksen
| Sociétés | Poste | Fin |
|---|---|---|
Affitech A/S
 Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | - |
| University of Oslo | Director/Board Member | - |
Medinnova AS
 Medinnova AS Investment ManagersFinance Medinnova AS (Medinnova) is the investment development subsidiary of Inven2 AS in Norway. The firm was established in 2003 to provide investment management services to hospitals and other health organizations, in addition to research communities in the Southern and Eastern regions of Norway. Located in Oslo, Medinnova provides consulting services and financing for projects that range from business development, research collaboration, innovation and industrial development, as well as administration of research funds for the national health service. The firm also serves as the Technology Transfer Office for university hospitals in the Oslo region, such as Rikshospitalet - Radiumhospitalet HF, Ullevål University Hospital HF, Aker University Hospital HF and Akershus University Hospital HF. | Corporate Officer/Principal | - |
Formation de Agnete Brunsvik Fredriksen
| University of Oslo | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MOLECULAR PARTNERS AG | Health Technology |
| NYKODE THERAPEUTICS | Health Technology |
| Entreprise privées | 3 |
|---|---|
Medinnova AS
Medinnova AS Investment ManagersFinance Medinnova AS (Medinnova) is the investment development subsidiary of Inven2 AS in Norway. The firm was established in 2003 to provide investment management services to hospitals and other health organizations, in addition to research communities in the Southern and Eastern regions of Norway. Located in Oslo, Medinnova provides consulting services and financing for projects that range from business development, research collaboration, innovation and industrial development, as well as administration of research funds for the national health service. The firm also serves as the Technology Transfer Office for university hospitals in the Oslo region, such as Rikshospitalet - Radiumhospitalet HF, Ullevål University Hospital HF, Aker University Hospital HF and Akershus University Hospital HF. | Finance |
Affitech A/S
Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Health Technology |
| Viginti AS |
